Saturday 17 October 2026
Export NTRB’s income statement to Excel — free account
Nutriband Inc.
NTRB Healthcare Biotechnology
Nutriband Inc.’s revenue for fiscal 2026 (year ended January 2026) was $2.0 million, down 4.80% from fiscal 2025. In the quarter to July 2026, revenue fell 29.7%, EPS grew 96.7%, free cash flow grew 55.5% and total debt fell 46.9%, each against the same quarter a year earlier.
6.22
0.05
−0.80%
Follow NTRB
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
21.42 | 26.10 | 26.81 | 35.61 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(59.22) | (83.54) | (74.61) | (46.30) | |
P/B ratio |
6.51 | 7.86 | 8.18 | 10.75 | |
Price to Tangible BV |
10.08 | 11.52 | 11.48 | 14.46 | |
EV/Sales |
19.36 | 23.93 | 24.61 | 33.33 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(8.62) | (9.89) | (9.76) | (13.46) | |
EV/FCF |
(8.61) | (9.88) | (9.75) | (13.45) | |
Quick Ratio |
3.80 | 4.82 | 5.98 | 7.07 | |
Current Ratio |
4.21 | 5.26 | 6.36 | 7.53 | |
Net Debt/EBITDA |
4.00 | 3.28 | 4.65 | 1.38 | |
Debt/Assets |
0.40% | 0.43% | 0.48% | 0.49% | |
Debt/Equity |
0.00 | 0.01 | 0.01 | 0.01 | |
Asset Turnover |
0.20 | 0.28 | 0.27 | 0.22 | |
Operating CF/Net income |
0.66 | 0.45 | 0.76 | 0.45 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(181.76) | (250.88) | (192.62) | (705.51) | |
Research and Development Expense of Revenue |
73.65% | 57.06% | 46.92% | 132.07% | |
Selling, General and Administrative Expense of Revenue |
171.50% | 277.78% | 230.05% | 1,008.87% | |
Intangible Assets out of Total Assets |
0.30 | 0.28 | 0.25 | 0.23 | |
Share Based Compensation of Revenue |
50.35% | 127.48% | 24.58% | 732.59% | |
Graham Net Nets |
0.08 | 0.07 | 0.08 | 0.06 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(20.09%) | (67.77%) | (56.35%) | (45.62%) | |
Free Cash Flow Yield |
(10.50%) | (9.28%) | (9.41%) | (6.96%) | |
Revenue per Share |
0.04 | 0.04 | 0.03 | 0.03 | |
Operating CF per Share |
(0.05) | (0.05) | (0.06) | (0.15) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.05) | (0.05) | (0.06) | (0.15) | |
Cash per Share |
0.28 | 0.33 | 0.39 | 0.44 | |
Shareholders Equity per Share |
0.44 | 0.49 | 0.57 | 0.63 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.44 | 0.49 | 0.57 | 0.63 | |
Free Cash Flow |
(0.58) | (0.56) | (0.73) | (1.75) | |
Working Capital |
2.91 | 3.54 | 4.20 | 5.04 | |
Capital Expenditures |
— | — | 0.00 | 0.00 | |
Net Current Asset Value |
2.86 | 3.47 | 4.12 | 4.94 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.09 | 0.05 | 0.10 | 0.13 | |
Average Payables |
1.02 | 0.68 | 0.60 | 0.75 | |
Average Inventory |
0.15 | 0.17 | 0.17 | 0.15 | |
Average Assets |
8.23 | 6.52 | 7.51 | 10.48 | |
Average Common Equity |
6.91 | 5.55 | 6.55 | 9.39 |
Columns are period end dates